Reporting quality of randomized, controlled trials evaluating immunotherapy in lung cancer-Reference-Cited by-同舟云学术

Reporting quality of randomized, controlled trials evaluating immunotherapy in lung cancer

Published:2021-08-25 Issue:20 Volume:12 Page:2732-2739
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Du Jun¹,Zhang Yundi²,Dong Yiting²,Duan Jianchun²^ORCID,Bai Hua²,Wang Jie²^ORCID,Xu Jiachen²^ORCID,Wang Zhijie²

Affiliation:

1. Office of Academic Research, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China

2. State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China

Funder

Natural Science Foundation of Beijing Municipality

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14114

Reference53 articles.

1. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

2. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non–Small Cell Lung Cancer

3. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

4. Prospective evaluation of thymosin fraction V immunotherapy in patients with non-small cell lung cancer receiving vindesine, doxorubicin, and cisplatin (VAP) chemotherapy

5. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The reporting quality of randomized controlled trials in pharmacotherapy for pituitary adenomas;Medicine;2024-03-15

2. The Deficits of the Methodological and Reporting Quality of Randomized Controlled Trials in the Field of Prosthetics and Orthotics in Iran: A Systematic Review;Reviews on Recent Clinical Trials;2023-05

3. Cross‐sectional study of the quality of randomized control trials on problem‐based learning in medical education;Clinical Anatomy;2022-11-16